Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
According to the recently published report 'Cyclin Dependent Kinase 2 - Drugs In Development, 2022'; Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 34 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B).
The report 'Cyclin Dependent Kinase 2 - Drugs In Development, 2022' outlays comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 3, 14 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Ear Nose Throat Disorders, Infectious Disease, Immunology, Metabolic Disorders, Respiratory and Undisclosed which include indications Breast Cancer, Ovarian Cancer, Solid Tumor, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2%li%Breast Cancer), Gastric Cancer, Lung Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Pancreatic Cancer, Peritoneal Cancer, Triple-Negative Breast Cancer (TNBC), Uterine Cancer, Coronavirus Disease 2019 (COVID-19), Endometrial Cancer, Hearing Disorders, Lymphoma, Non-Small Cell Lung Cancer, Prostate Cancer, Unspecified Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Cystic Fibrosis, Diffuse Large B-Cell Lymphoma, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Gliosarcoma, Hematological Tumor, Hepatocellular Carcinoma, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Inflammation, Laryngeal Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, Small-Cell Lung Cancer, T-Cell Lymphomas, Thymic Carcinoma, Thyroid Cancer, Unspecified and Unspecified B-Cell Lymphomas.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Cyclin Dependent Kinase 2 - Drugs In Development, 2022'; Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 34 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes.
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B).
The report 'Cyclin Dependent Kinase 2 - Drugs In Development, 2022' outlays comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 3, 14 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Ear Nose Throat Disorders, Infectious Disease, Immunology, Metabolic Disorders, Respiratory and Undisclosed which include indications Breast Cancer, Ovarian Cancer, Solid Tumor, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2%li%Breast Cancer), Gastric Cancer, Lung Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Pancreatic Cancer, Peritoneal Cancer, Triple-Negative Breast Cancer (TNBC), Uterine Cancer, Coronavirus Disease 2019 (COVID-19), Endometrial Cancer, Hearing Disorders, Lymphoma, Non-Small Cell Lung Cancer, Prostate Cancer, Unspecified Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Cystic Fibrosis, Diffuse Large B-Cell Lymphoma, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Gliosarcoma, Hematological Tumor, Hepatocellular Carcinoma, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Inflammation, Laryngeal Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, Small-Cell Lung Cancer, T-Cell Lymphomas, Thymic Carcinoma, Thyroid Cancer, Unspecified and Unspecified B-Cell Lymphomas.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
- The report reviews Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Drug Profiles
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Apr 12, 2022: Cyclacel Pharmaceuticals announces publication confirming fadraciclib suppresses MCL1 and synergizes with venetoclax in chronic lymphocytic leukemia
Mar 08, 2022: Blueprint Medicines to showcase poster presentation on BLU-222 at AACR Annual Meeting 2022
Dec 28, 2021: Regor Therapeutics announces U.S. FDA authorization to conduct Regor's first-in-human clinical trial with the next generation targeted inhibitor RGT-419B for oncology
Nov 05, 2021: Cyclacel announces dosing of first patient in phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes
Jul 13, 2021: Cyclacel announces dosing of first patient in phase 1/2 study of oral fadraciclib in patients with advanced solid tumors and aggressive lymphomas
May 05, 2021: Tiziana announces strategic initiative with Takanawa Japan K.K., Pharma team, to identify a partner in Japan and other Asian countries for further clinical development of Milciclib in patients with advanced hepatocellular carcinoma
Jan 14, 2021: Adastra Pharmaceuticals, present at Inaugural B. Riley Securities' Oncology Investor Conference
Jan 13, 2021: Adastra Pharmaceuticals announces positive top-line data from phase 1b clinical trial of Zotiraciclib in the treatment of recurrent high-grade gliomas
Oct 26, 2020: Cyclacel presents phase 1 clinical data showing safety, anti-tumor activity and good oral bioavailability of fadraciclib in patients with advanced solid tumors at the EORTC-NCI-AACR Symposium 2020
Oct 06, 2020: ICR to study fadraciclib to treat paediatric neuroblastoma
Sep 21, 2020: Cyclacel announces Fadraciclib abstract selected for oral presentation in the Late Breaking and Best Proffered Paper session at the 32nd EORTC-NCI-AACR Symposium 2020
Aug 21, 2020: Tiziana granted a patent on the use of milciclib in combination with tyrosine kinase inhibitors for treatment of hepatocellular carcinoma and other cancers
Jul 13, 2020: Cyclacel’s clinical stage CDK2/9 inhibitor Fadraciclib targets key anti-apoptotic and oncogenic pathways in cancer
May 14, 2020: Tiziana Lifesciences announces online publication of two abstracts at the American Society of Clinical Oncology (ASCO) reporting clinical activity and safety of Milciclib in patients with advanced hepatocellular carcinoma
May 11, 2020: Tiziana Life Sciences announces publishing of two e-abstracts featuring its Miliciclib
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Drug Profiles
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Apr 12, 2022: Cyclacel Pharmaceuticals announces publication confirming fadraciclib suppresses MCL1 and synergizes with venetoclax in chronic lymphocytic leukemia
Mar 08, 2022: Blueprint Medicines to showcase poster presentation on BLU-222 at AACR Annual Meeting 2022
Dec 28, 2021: Regor Therapeutics announces U.S. FDA authorization to conduct Regor's first-in-human clinical trial with the next generation targeted inhibitor RGT-419B for oncology
Nov 05, 2021: Cyclacel announces dosing of first patient in phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes
Jul 13, 2021: Cyclacel announces dosing of first patient in phase 1/2 study of oral fadraciclib in patients with advanced solid tumors and aggressive lymphomas
May 05, 2021: Tiziana announces strategic initiative with Takanawa Japan K.K., Pharma team, to identify a partner in Japan and other Asian countries for further clinical development of Milciclib in patients with advanced hepatocellular carcinoma
Jan 14, 2021: Adastra Pharmaceuticals, present at Inaugural B. Riley Securities' Oncology Investor Conference
Jan 13, 2021: Adastra Pharmaceuticals announces positive top-line data from phase 1b clinical trial of Zotiraciclib in the treatment of recurrent high-grade gliomas
Oct 26, 2020: Cyclacel presents phase 1 clinical data showing safety, anti-tumor activity and good oral bioavailability of fadraciclib in patients with advanced solid tumors at the EORTC-NCI-AACR Symposium 2020
Oct 06, 2020: ICR to study fadraciclib to treat paediatric neuroblastoma
Sep 21, 2020: Cyclacel announces Fadraciclib abstract selected for oral presentation in the Late Breaking and Best Proffered Paper session at the 32nd EORTC-NCI-AACR Symposium 2020
Aug 21, 2020: Tiziana granted a patent on the use of milciclib in combination with tyrosine kinase inhibitors for treatment of hepatocellular carcinoma and other cancers
Jul 13, 2020: Cyclacel’s clinical stage CDK2/9 inhibitor Fadraciclib targets key anti-apoptotic and oncogenic pathways in cancer
May 14, 2020: Tiziana Lifesciences announces online publication of two abstracts at the American Society of Clinical Oncology (ASCO) reporting clinical activity and safety of Milciclib in patients with advanced hepatocellular carcinoma
May 11, 2020: Tiziana Life Sciences announces publishing of two e-abstracts featuring its Miliciclib
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Apollo Therapeutics LLC, 2022
Pipeline by Astex Pharmaceuticals Inc, 2022
Pipeline by Aucentra Therapeutics Pty Ltd, 2022
Pipeline by BioTheryX Inc, 2022
Pipeline by Blueprint Medicines Corp, 2022
Pipeline by Cedilla Therapeutics, 2022
Pipeline by Cothera Bioscience Pty Ltd, 2022
Pipeline by Cyclacel Pharmaceuticals Inc, 2022
Pipeline by Incyclix Bio LLC, 2022
Pipeline by Incyte Corp, 2022
Pipeline by Monte Rosa Therapeutics Inc, 2022
Pipeline by Neosome Life Sciences LLC, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Plexium Inc, 2022
Pipeline by Prous Institute for Biomedical Research SA, 2022
Pipeline by Qilu Regor Therapeutics Inc, 2022
Pipeline by Relay Therapeutics Inc, 2022
Pipeline by Rhizen Pharmaceuticals SA, 2022
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Pipeline by Ting Therapeutics LLC, 2022
Pipeline by Tiziana Life Sciences Plc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Apollo Therapeutics LLC, 2022
Pipeline by Astex Pharmaceuticals Inc, 2022
Pipeline by Aucentra Therapeutics Pty Ltd, 2022
Pipeline by BioTheryX Inc, 2022
Pipeline by Blueprint Medicines Corp, 2022
Pipeline by Cedilla Therapeutics, 2022
Pipeline by Cothera Bioscience Pty Ltd, 2022
Pipeline by Cyclacel Pharmaceuticals Inc, 2022
Pipeline by Incyclix Bio LLC, 2022
Pipeline by Incyte Corp, 2022
Pipeline by Monte Rosa Therapeutics Inc, 2022
Pipeline by Neosome Life Sciences LLC, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Plexium Inc, 2022
Pipeline by Prous Institute for Biomedical Research SA, 2022
Pipeline by Qilu Regor Therapeutics Inc, 2022
Pipeline by Relay Therapeutics Inc, 2022
Pipeline by Rhizen Pharmaceuticals SA, 2022
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Pipeline by Ting Therapeutics LLC, 2022
Pipeline by Tiziana Life Sciences Plc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
